Mark Minden - Publications

Affiliations: 
University of Toronto, Toronto, ON, Canada 
Area:
Molecular Biology

116 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Tin E, Lee J, Khatri I, Na Y, Minden MD, Zhang L. Double-negative T cells utilize a TNFα-JAK1-ICAM-1 cytotoxic axis against acute myeloid leukemia. Blood Advances. PMID 38547431 DOI: 10.1182/bloodadvances.2023011739  0.318
2023 Zeng AGX, Iacobucci I, Shah S, Mitchell A, Wong G, Bansal S, Gao Q, Kim H, Kennedy JA, Minden MD, Haferlach T, Mullighan CG, Dick JE. Precise single-cell transcriptomic mapping of normal and leukemic cell states reveals unconventional lineage priming in acute myeloid leukemia. Biorxiv : the Preprint Server For Biology. PMID 38234771 DOI: 10.1101/2023.12.26.573390  0.312
2020 Soares F, Chen B, Lee JB, Ahmed M, Ly D, Tin E, Kang H, Zeng Y, Akhtar N, Minden MD, He H, Zhang L. CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy. Blood. PMID 33270841 DOI: 10.1182/blood.2019004108  0.31
2020 Sibai H, Chen R, Liu X, Falcone U, Schimmer A, Schuh A, Law A, McNamara C, Maze D, Yee K, Minden M, Chan SM, Gupta V, Murphy T, Sakurai N, et al. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. British Journal of Haematology. PMID 32395867 DOI: 10.1111/Bjh.16695  0.306
2019 Andrews C, Atenafu EG, Murphy T, Al-Shaibani Z, Chan SM, Gupta V, Kim DDH, Kumar R, Lam W, Lipton JH, Mattsson J, Maze D, Michelis F, McNamara CJ, Schimmer AD, ... ... Minden MD, et al. Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia Blood. 134: 5725-5725. DOI: 10.1016/J.Bbmt.2019.12.642  0.346
2018 Khoury H, He R, Schimmer A, Beadle JR, Hostetler KY, Minden MD. Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia. Chemotherapy. 63: 225-237. PMID 30372692 DOI: 10.1159/000491705  0.306
2018 Luciani GM, Xie L, Dilworth D, Tierens A, Moskovitz Y, Murison A, Szewczyk MM, Mitchell A, Lupien M, Shlush L, Dick JE, Arrowsmith CH, Barsyte-Lovejoy D, Minden MD. Characterization of inv(3) cell line OCI-AML-20 with stroma dependent CD34 expression. Experimental Hematology. PMID 30352278 DOI: 10.1016/J.Exphem.2018.10.006  0.302
2018 Garcia Prat L, Dobson SM, Chan-Seng-Yue M, Vanner R, Murison A, Wintersinger J, Waanders E, Gan OI, McLeod J, Payne-Turner D, Edmonson M, Gu Z, Ma X, Fan Y, Gupta P, ... ... Minden MD, et al. Relapse-Initiating Clones Preexisting at Diagnosis in B- Cell Acute Lymphoblastic Leukemia Help Predict Molecular Pathways of Relapse Blood. 132: 915-915. DOI: 10.1182/Blood-2018-99-118998  0.303
2018 Vanner RJ, Dobson SM, Grandal I, Gan O, McLeod J, Kennedy J, Voisin V, Daghrach A, Schoof EM, Guidos C, Danska J, Waanders E, Minden M, Mullighan CG, Dick JE. Abstract 5173: Genetic profiling of central nervous system dissemination of B-acute lymphoblastic leukemia reveals clonal selection and therapeutic vulnerability Cancer Research. 78: 5173-5173. DOI: 10.1158/1538-7445.Am2018-5173  0.414
2018 Crews LA, Lazzari E, Mondala PK, Santos ND, Miller A, Pineda G, Jiang Q, Ganesan A, Wu C, Costello C, Minden M, Chiaramonte R, Stewart AK, Jamieson CHM. Abstract 4437: Down-modulation of ADAR1-mediated GLI1 editing alters extracellular and immune response genes in multiple myeloma Cancer Research. 78: 4437-4437. DOI: 10.1158/1538-7445.Am2018-4437  0.393
2018 Boileau M, Shirinian M, Gayden T, Harutyunyan A, Chen C, Mikael L, Duncan H, Neumann A, Arreba-Tutusaus P, De Jay N, Zeinieh M, Nikbakht H, Mouawad C, Massoud R, Frey F, ... ... Minden M, et al. Mutations in Human Histone H3 are Pre-Leukemic Events and Promote Hematopoietic Stem Cell Expansion and Leukemic Aggressiveness Experimental Hematology. 64: S55-S56. DOI: 10.1016/J.Exphem.2018.06.195  0.304
2018 Murphy T, Zou J, Daher-Reyes GS, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KW, Stockley TL, Kamel-Reid S, Maze D, Bratman S, Schuh A, Chan SM. Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations Blood. 132: 992-992. DOI: 10.1016/J.Clml.2019.07.113  0.352
2017 Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, Leu H, Ali SA, Ganesan AP, Wu CN, Costello C, Minden M, Chiaramonte R, Stewart AK, Crews LA, et al. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nature Communications. 8: 1922. PMID 29203771 DOI: 10.1038/S41467-017-01890-W  0.351
2017 Kagoya Y, Tanaka S, Butler MO, Minden M, Hirano N. Abstract PR09: A novel chimeric antigen receptor containing JAK-STAT signaling domains mediates superior antitumor effects Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-Pr09  0.395
2017 Lazzari E, Santos ND, Wu C, Leu H, Pineda G, Ali S, Costello C, Minden M, Chiaramonte R, Crews L, Jamieson C. Abstract 3351: Aberrant RNA editing of GLI1 promotes malignant regeneration in multiple myeloma Cancer Research. 77: 3351-3351. DOI: 10.1158/1538-7445.Am2017-3351  0.381
2016 Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ, Pineda G, Morris SR, Mason CN, Geron I, Barrett C, Goff DJ, Wall R, Pellecchia M, Minden M, et al. ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell. PMID 27292188 DOI: 10.1016/J.Stem.2016.05.004  0.363
2016 Woolley JF, Son MH, Dzneladze I, He R, Mangialardi E, Gabra M, Sharobim M, Minden MD, Salmena L. A Novel Role for INPP4B in Haematopoiesis and Leukemia Blood. 128: 1720-1720. DOI: 10.1182/blood.v128.22.1720.1720  0.315
2016 Jeyaraju DV, Voisin V, Ramakrishnan A, Hurren R, Maclean N, Gronda M, Minden M, Bader G, Schimmer AD. Abstract A87: Targeting the mitochondrial quality control machinery in acute myeloid leukemia Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A87  0.357
2016 Lazzari E, Crews LA, Wu C, Leu H, Ali S, Chiaramonte R, Minden M, Costello C, Jamieson CHM. Abstract 2414: ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies Cancer Research. 76: 2414-2414. DOI: 10.1158/1538-7445.Am2016-2414  0.382
2015 Gao C, Leyton JV, Schimmer AD, Minden M, Reilly RM. Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 110: 1-7. PMID 26748017 DOI: 10.1016/J.Apradiso.2015.12.043  0.357
2015 Leyton JV, Gao C, Williams B, Keating A, Minden M, Reilly RM. A radiolabeled antibody targeting CD123(+) leukemia stem cells - initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML. Leukemia Research Reports. 4: 55-9. PMID 26500848 DOI: 10.1016/J.Lrr.2015.07.003  0.345
2015 Kadia TM, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. American Journal of Hematology. 90: E139-41. PMID 25858582 DOI: 10.1002/Ajh.24036  0.35
2015 Lee JB, Chen WC, Streck E, Kang S, Minden MD, Dick JE, Zhang L. Efficacy and Safety of Allogeneic Double Negative T Cell As a Cellular Therapy for AML and Its Underlying Mechanism Blood. 126: 1355-1355. DOI: 10.1182/BLOOD.V126.23.1355.1355  0.347
2015 Thomas M, Sukhai M, Zhang T, Harbi D, Souza JD, MacDonald K, Pugh T, Minden M, Schuh A, Stockley TL, Kamel-Reid S. Abstract 4260: Clinical testing and implementation of the TruSight Myeloid Next Generation Sequencing (NGS) panel for identification of clinically relevant variants in hematological malignancies Cancer Research. 75: 4260-4260. DOI: 10.1158/1538-7445.Am2015-4260  0.326
2015 Kadia T, Thomas X, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, De Porre P, Xiu L, Doyle M, Bussolari J, Kantarjian H. Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts Clinical Lymphoma Myeloma and Leukemia. 15: S192. DOI: 10.1016/J.Clml.2015.04.042  0.356
2014 Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells. Leukemia Research. 38: 1367-73. PMID 25278187 DOI: 10.1016/J.Leukres.2014.09.005  0.355
2014 Couban S, Savoie L, Mourad YA, Leber B, Minden M, Turner R, Palada V, Shehata N, Christofides A, Lachance S. Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus. Current Oncology (Toronto, Ont.). 21: e265-309. PMID 24764712 DOI: 10.3747/Co.21.1834  0.367
2014 Nissim R, Rodin G, Schimmer A, Minden M, Rydall A, Yuen D, Mischitelle A, Fitzgerald P, Lo C, Gagliese L, Zimmermann C. Finding new bearings: a qualitative study on the transition from inpatient to ambulatory care of patients with acute myeloid leukemia. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 22: 2435-43. PMID 24705856 DOI: 10.1007/S00520-014-2230-3  0.304
2014 Rashid A, Fateen M, Juan R, Laister RC, Minden M. Abstract 3604: Investigation of the role of CSF-1 and its receptor in the bone marrow stroma microenvironment in acute myeloid leukemia Cancer Research. 74: 3604-3604. DOI: 10.1158/1538-7445.Am2014-3604  0.381
2014 Dobson S, Waanders E, Grandal I, Gan O, McLeod J, Minden M, Guidos C, Danska J, Mullighan C, Dick J. Evolving heterogeneity in acute lymphoblastic leukemia Experimental Hematology. 42: S31. DOI: 10.1016/J.Exphem.2014.07.109  0.324
2013 Tung S, Shi Y, Wong K, Zhu F, Gorczynski R, Laister RC, Minden M, Blechert AK, Genzel Y, Reichl U, Spaner DE. PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 122: 969-80. PMID 23814018 DOI: 10.1182/Blood-2013-03-489468  0.314
2013 Zhang H, Mi JQ, Fang H, Wang Z, Wang C, Wu L, Zhang B, Minden M, Yang WT, Wang HW, Li JM, Xi XD, Chen SJ, Zhang J, Chen Z, et al. Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proceedings of the National Academy of Sciences of the United States of America. 110: 5606-11. PMID 23513221 DOI: 10.1073/Pnas.1302352110  0.409
2013 Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, ... ... Minden M, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genetics. 45: 242-52. PMID 23334668 DOI: 10.1038/Ng.2532  0.357
2013 Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, ... ... Minden M, et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 12: 316-28. PMID 23333150 DOI: 10.1016/J.Stem.2012.12.011  0.387
2013 Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao KH, Morris SR, Goldstein LS, Marra MA, et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 110: 1041-6. PMID 23275297 DOI: 10.1073/Pnas.1213021110  0.415
2013 Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, Sriskanthadevan S, Sun H, Wang X, Skrtic M, Seneviratne A, Cusimano M, Jhas B, Gronda M, MacLean N, Cho EE, ... ... Minden MD, et al. Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors Journal of Clinical Investigation. 123: 315-328. PMID 23202731 DOI: 10.1172/Jci64180  0.306
2013 Chen WC, Popescu AC, Xing Y, Gerhard G, Yuan J, Minden M, Guidos C, Hogge DE, Dick JE, Wang JC. Abstract 907: Efficacy of SAR302503, a JAK2 inhibitor, in primary human acute myeloid leukemia xenografts. Cancer Research. 73: 907-907. DOI: 10.1158/1538-7445.Am2013-907  0.38
2013 Rashid A, Fateen M, Schimmer A, Minden M. Abstract 4123: Investigation of growth factor signaling through macrophage colony stimulating factor (CSF-1) and its receptor (FMS) in the bone marrow stromal microenvironment in acute myeloid leukemia (AML). Cancer Research. 73: 4123-4123. DOI: 10.1158/1538-7445.Am2013-4123  0.365
2013 Jiang Q, Crews LA, Barrett CL, Court-Recart A, Goff D, Sadarangani A, Rusert J, Morris S, Goldstein L, Chun H, Marra M, Fraser K, Dao K, Minden M, Jamieson C. Abstract 247: ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Cancer Research. 73: 247-247. DOI: 10.1158/1538-7445.Am2013-247  0.417
2013 Lechman ER, Hermans KG, Dobson S, Eppert K, Minden M, Dick JE. Abstract 2292: Enforced expression of miR-125b promotes the in vivo expansion of human Lin- CB multi-lymphoid progenitors (MLP) and AML leukemia stem cells. Cancer Research. 73: 2292-2292. DOI: 10.1158/1538-7445.Am2013-2292  0.354
2012 Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, ... ... Minden M, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2670-7. PMID 22689805 DOI: 10.1200/Jco.2011.38.9429  0.316
2012 Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA, Marton L, Woster P, Minden MD, Dugas M, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine. 18: 605-11. PMID 22406747 DOI: 10.1038/Nm.2661  0.305
2012 Balaian L, Sadarangani A, Widhopf GF, Zhong R, Prussak C, Marra MA, Dick JE, Minden MD, Ball ED, Carson DA, Jamieson C, Kipps TJ. A Highly Selective Anti-ROR1 Monoclonal Antibody Inhibits Human Acute Myeloid Leukemia CD34+ Cell Survival and Self-Renewal. Blood. 120: 2560-2560. DOI: 10.1182/Blood.V120.21.2560.2560  0.311
2012 Lechman ER, Gentner B, Galen Pv, Eppert K, Takenaka K, Minden M, Naldini L, Dick JE. Abstract 1013: Enriched miR-126 bioactivity marks the primitive compartment in human AML and regulates leukemia stem cell numbers Cancer Research. 72: 1013-1013. DOI: 10.1158/1538-7445.Am2012-1013  0.331
2012 Niapour M, Farr C, Minden M, Berger SA. Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression Blood Cancer Journal. 2. DOI: 10.1038/Bcj.2011.50  0.34
2011 Merims S, Li X, Joe B, Dokouhaki P, Han M, Childs RW, Wang ZY, Gupta V, Minden MD, Zhang L. Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. Leukemia. 25: 1415-22. PMID 21566657 DOI: 10.1038/leu.2011.99  0.302
2011 Sukhai MA, Hurren R, Rutledge A, Livak B, Wang X, Seneviratne A, Cusimano MC, Gebbia M, Skrtic M, Sun H, Gronda M, Spagnuolo PA, Urbanus M, Eppert K, Dissanayake D, ... ... Minden MD, et al. Lysosomal Disruption Selectively Targets Leukemia Cells and Leukemia Stem Cells Through A Mechanism Related to Increased Reactive Oxygen Species Production Blood. 118: 61-61. DOI: 10.1182/Blood.V118.21.61.61  0.3
2011 Shih AY, Schairer A, Barrett CL, Geron I, Recart ACC, Goff D, Prashad S, Wu J, Jiang Q, Gotlib J, Balaian L, Minden MD, Leu H, Wall R, Ma W, et al. Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist, Blood. 118: 3776-3776. DOI: 10.1182/Blood.V118.21.3776.3776  0.308
2010 Kerkel K, Schupf N, Hatta K, Pang D, Salas M, Kratz A, Minden M, Murty V, Zigman WB, Mayeux RP, Jenkins EC, Torkamani A, Schork NJ, Silverman W, Croy BA, et al. Altered DNA methylation in leukocytes with trisomy 21. Plos Genetics. 6: e1001212. PMID 21124956 DOI: 10.1371/Journal.Pgen.1001212  0.341
2010 Wang K, Wang P, Shi J, Zhu X, He M, Jia X, Yang X, Qiu F, Jin W, Qian M, Fang H, Mi J, Yang X, Xiao H, Minden M, et al. PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell. 17: 186-97. PMID 20159610 DOI: 10.1016/J.Ccr.2009.12.045  0.328
2010 Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia & Lymphoma. 51: 252-60. PMID 20109071 DOI: 10.3109/10428190903585286  0.32
2010 Cencic R, Carrier M, Trnkus A, Porco JA, Minden M, Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leukemia Research. 34: 535-41. PMID 19726085 DOI: 10.1016/J.Leukres.2009.07.043  0.344
2010 Rodin G, Lo C, Rydall A, Chan A, Andrews J, Minden M, Schimmer A, Brandwein J, Zimmermann C. Comparison of distress in patients with acute leukemia and advanced solid tumors. Journal of Clinical Oncology. 28: e19537-e19537. DOI: 10.1200/Jco.2010.28.15_Suppl.E19537  0.319
2010 Thomas M, Sukhai M, Schuh N, Xuan Y, Minden M, Kamel-Reid S. Abstract 1240: Functional deregulation of NF-kB and abnormal TNFa response in acute promyelocytic leukemia Cancer Research. 70: 1240-1240. DOI: 10.1158/1538-7445.Am10-1240  0.433
2009 Borthakur G, Faderl S, Ravandi F, Padmanabhan S, Stock W, Wu K, Li J, Curt G, Tallman M, Minden M. Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3580. PMID 27961757 DOI: 10.1200/Jco.2009.27.15_Suppl.3580  0.36
2009 Yogaparan T, Panju A, Minden M, Brandwein J, Mohamedali HZ, Alibhai SMH. Information needs of adult patients 50 or older with newly diagnosed acute myeloid leukemia Leukemia Research. 33: 1288-1290. PMID 19167065 DOI: 10.1016/J.Leukres.2008.12.008  0.301
2009 Eppert K, Takenaka K, Nilsson B, Lechman ER, Ling V, Beyene J, Canty AJ, Danska JS, Minden MD, Golub TR, Ebert BL, Dick JE. Leukemic and Normal Stem Cell Transcriptional Signatures Determined by Functional Assays Are Predictive of the Overall Survival of AML Patients. Blood. 114: 389-389. DOI: 10.1182/Blood.V114.22.389.389  0.331
2008 Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, ... ... Minden M, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 112: 981-9. PMID 18495956 DOI: 10.1182/Blood-2007-10-115873  0.329
2008 Siegal D, Xu W, Sutherland R, Kamel-Reid S, Kuruvilla J, Lipton JH, Minden M, Messner H, Gupta V. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplantation. 42: 51-6. PMID 18372907 DOI: 10.1038/Bmt.2008.88  0.325
2008 Al-Khabori MK, Minden M, Gupta V, Schimmer AD, Schuh AC, Yee KW, Xu W, Brandwein JM. Treatment of Adult T-ALL with a Pediatric Asparaginase-Intensive Protocol Results in Survival Benefit When Compared to Other Adult Based Protocols Blood. 112: 3956-3956. DOI: 10.1182/Blood.V112.11.3956.3956  0.348
2008 Minden M, Rosen D, Putta S, Cohen A, Francis-Lang H, Covey T, Woronicz J, Soper D, Long B, Cordeiro J, Panganiban-Lustan L, Banville S, Gayko U, Cesano A, Fantl W. Distinct Proteomic Signaling Networks Stratify Responses to Ara-C Based Induction Therapy in Patients with Acute Myeloid Leukemia (AML) Blood. 112: 2549-2549. DOI: 10.1182/Blood.V112.11.2549.2549  0.345
2008 Khoury H, Suarez-Saiz F, Wu S, San-Marina S, Minden M. An Upstream Insulator Element Regulates DLK1 Imprinting in AML Blood. 112: 202-202. DOI: 10.1182/Blood.V112.11.202.202  0.368
2008 Mohamedali H, Breunis H, Minden M, Alibhai S. Information needs of adults patients with newly diagnosed acute myeloid leukaemia (AML) Critical Reviews in Oncology/Hematology. 68: S51. DOI: 10.1016/S1040-8428(08)70119-7  0.314
2007 Bastianutto C, Mian A, Symes J, Mocanu J, Alajez N, Sleep G, Shi W, Keating A, Crump M, Gospodarowicz M, Medin J, Minden M, Liu FF. Local radiotherapy induces homing of hematopoietic stem cells to the irradiated bone marrow. Cancer Research. 67: 10112-6. PMID 17974951 DOI: 10.1158/0008-5472.Can-07-2192  0.306
2007 Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, Kuruvilla J, Lipton JH, Minden M, Messner HA. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 1233-43. PMID 17889361 DOI: 10.1016/J.Bbmt.2007.07.003  0.322
2007 Zaretsky Y, Rifkind J, Lockwood G, Tsang R, Kiss T, Hasegawa W, Fyles G, Tejpar I, Loach D, Minden M, Messner H, Lipton JH. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning. Bone Marrow Transplantation. 40: 423-30. PMID 17603516 DOI: 10.1038/Sj.Bmt.1705755  0.317
2007 Kim DH(, Popradi G, Kuruvilla J, Gupta V, Minden M, Lipton JH, Messner HA. Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies. Blood. 110: 5039-5039. DOI: 10.1182/Blood.V110.11.5039.5039  0.338
2007 McIntosh CA, Saiz FJS, Minden MD. SOCS2 Expression in AML: A Context Dependent Effect?. Blood. 110: 4152-4152. DOI: 10.1182/BLOOD.V110.11.4152.4152  0.301
2007 Popradi G, Kim DH(, Kuruvilla J, Gupta V, Minden M, Lipton JH, Messner HA. Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS. Blood. 110: 1102-1102. DOI: 10.1182/Blood.V110.11.1102.1102  0.336
2007 Kim DH(, Popradi G, Kuruvilla J, Gupta V, Minden M, Messner HA, Lipton JH. Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). Blood. 110: 1062-1062. DOI: 10.1182/Blood.V110.11.1062.1062  0.324
2006 Lee S, Chen J, Zhou G, Shi RZ, Bouffard GG, Kocherginsky M, Ge X, Sun M, Jayathilaka N, Kim YC, Emmanuel N, Bohlander SK, Minden M, Kline J, Ozer O, et al. Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proceedings of the National Academy of Sciences of the United States of America. 103: 1030-5. PMID 16418266 DOI: 10.1073/Pnas.0509878103  0.443
2006 Garcia-Manero G, Minden M, Estrov Z, Verstovsek S, Newsome WM, Reid G, Besterman J, Li Z, Pearce L, Martell R. Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS) Journal of Clinical Oncology. 24: 6500-6500. DOI: 10.1200/Jco.2006.24.18_Suppl.6500  0.326
2006 Gupta V, Keng C, Xu W, Brandwein J, Schimmer A, Schuh A, Yee K, Minden M, Alibhai S. Presence of Comorbidities Do Not Predict Early Mortality or Survival in Older Patients (≥60 Years) with Acute Myeloid Leukemia (AML) Undergoing Intensive Induction Therapy. Blood. 108: 4489-4489. DOI: 10.1182/Blood.V108.11.4489.4489  0.322
2005 Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S, Tsang R, Yi QL, Minden M, Messner H, Kiss T. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 764-72. PMID 16182177 DOI: 10.1016/J.Bbmt.2005.06.006  0.377
2005 Meng YS, Khoury H, Dick JE, Minden MD. Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia Leukemia. 19: 1941-1947. PMID 16094422 DOI: 10.1038/sj.leu.2403836  0.337
2005 Lübbert M, Minden M. Decitabine in acute myeloid leukemia. Seminars in Hematology. 42: S38-42. PMID 16015504 DOI: 10.1053/J.Seminhematol.2005.05.007  0.355
2005 Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer. 103: 2082-90. PMID 15830348 DOI: 10.1002/Cncr.21006  0.349
2005 Au PY, Martin N, Chau H, Moemeni B, Chia M, Liu FF, Minden M, Yeh WC. The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF. Oncogene. 24: 3196-205. PMID 15735680 DOI: 10.1038/Sj.Onc.1208516  0.309
2005 Garcia-Manero G, Minden M, Estrov Z, Verstovsek S, Fiorentino J, Kantarjian H, Reid G, Martell RE. A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS). Blood. 106: 4639-4639. DOI: 10.1182/Blood.V106.11.4639.4639  0.318
2004 Crump M, Leber B, Kassis J, Hedley D, Minden M, Buckstein R, McIntosh L, Eisenhauer E, Seymour L. A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6611. PMID 28016333 DOI: 10.1200/Jco.2004.22.14_Suppl.6611  0.3
2004 Tinmouth A, Tannock IF, Crump M, Tomlinson G, Brandwein J, Minden M, Sutton D. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion. 44: 1711-9. PMID 15584985 DOI: 10.1111/J.0041-1132.2004.04118.X  0.311
2004 Shago M, Bouman D, Kamel-Reid S, Minden M, Chun K. Cryptic insertion of MLL gene into 9p22 leads to MLL-MLLT3 (AF9) fusion in a case of acute myelogenous leukemia. Genes, Chromosomes and Cancer. 40: 349-354. PMID 15188459 DOI: 10.1002/Gcc.20045  0.397
2004 Ichim CV, Sukhai MA, Brandwein J, Minden MD, Schimmer AD, Schuh AC, Kamel-Reid S, Iscove NN, Wells RA. EAR-2: Identification of a Gene Involved in Maintenance of Clonogenicity in Haematopoiesis. Blood. 104: 3226-3226. DOI: 10.1182/Blood.V104.11.3226.3226  0.333
2004 Aswald JM, Wang X, Aswald S, Benoit LA, Minden M, Messner HA, Keating A. Autologous Gamma-Delta T (GD-T) Cells in Acute Myeloid Leukemia (AML): Potential Immune Effector Cells for Minimal Disease?. Blood. 104: 2538-2538. DOI: 10.1182/Blood.V104.11.2538.2538  0.424
2003 Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M, Suh N, Sporn M, Reed JC. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL Leukemia. 17: 2122-2129. PMID 12931220 DOI: 10.1038/Sj.Leu.2403112  0.319
2003 Kolomietz F, Marrano P, Yee K, Thai B, Braude I, Kolomietz A, Chun K, Minkin S, Kamel-Reid S, Minden M, Squire JA. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome Leukemia. 17: 1313-1323. PMID 12835719 DOI: 10.1038/Sj.Leu.2402969  0.384
2002 Soboloff J, Zhang Y, Minden M, Berger SA. Sensitivity of myeloid leukemia cells to calcium influx blockade: Application to bone marrow purging Experimental Hematology. 30: 1219-1226. PMID 12384154 DOI: 10.1016/S0301-472X(02)00893-7  0.361
2000 Lakosha H, Simpson R, Patterson B, Minden M, Payne D, Lipton JH. Acute lymphocytic blast crisis as an ocular manifestation of chronic granulocytic leukemia Canadian Journal of Ophthalmology-Journal Canadien D Ophtalmologie. 35: 336-339. PMID 11091917 DOI: 10.1016/S0008-4182(00)80063-0  0.341
1999 Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, Stewart K, Beare S, Eisenhauer E. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. Leukemia. 13: 343-7. PMID 10086724 DOI: 10.1038/Sj.Leu.2401308  0.322
1998 Wang JCY, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, Nayar R, Laraya P, Minden M, Keating A, Eaves AC, Eaves CJ, Dick JE. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase Blood. 91: 2406-2414. PMID 9516140 DOI: 10.1182/Blood.V91.7.2406.2406_2406_2414  0.399
1997 Dong WF, Heng HH, Lowsky R, Xu Y, DeCoteau JF, Shi XM, Tsui LC, Minden MD. Cloning, expression, and chromosomal localization to 11p12-13 of a human LIM/HOMEOBOX gene, hLim-1. Dna and Cell Biology. 16: 671-8. PMID 9212161 DOI: 10.1089/Dna.1997.16.671  0.728
1997 Wu HK, Minden MD. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl. Biochemical and Biophysical Research Communications. 234: 742-7. PMID 9175786 DOI: 10.1006/bbrc.1997.6592  0.332
1997 Wu HK, Minden MD. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl. Biochemical and Biophysical Research Communications. 233: 806-12. PMID 9168938 DOI: 10.1006/bbrc.1997.6546  0.331
1997 Lowsky R, DeCoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y, Mak TW, Kadin ME, Minden MD. Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). Blood. 89: 2276-82. PMID 9116269  0.726
1996 Wu HK, Heng HH, Siderovski DP, Dong WF, Okuno Y, Shi XM, Tsui LC, Minden MD. Identification of a human LIM-Hox gene, hLH-2, aberrantly expressed in chronic myelogenous leukaemia and located on 9q33-34.1. Oncogene. 12: 1205-12. PMID 8649822  0.723
1996 Dong WF, Billia F, Atkins HL, Iscove NN, Minden MD. Expression of rhombotin 2 in normal and leukaemic haemopoietic cells. British Journal of Haematology. 93: 280-6. PMID 8639417  0.745
1996 Lowsky R, Fyles G, Minden M, Lipton J, Meharchand J, Tejpar I, Zipursky A, Messner H. Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization British Journal of Haematology. 93: 163-165. PMID 8611454 DOI: 10.1046/J.1365-2141.1996.454991.X  0.384
1995 Dong WF, Xu Y, Hu QL, Munroe D, Minowada J, Housman DE, Minden MD. Molecular characterization of a chromosome translocation breakpoint t(11;14)(p13;q11) from the cell line KOPT-K1. Leukemia. 9: 1812-7. PMID 7475267  0.716
1994 Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I, Atkins H, Sutcliffe S, Messner H. Secondary malignancies after bone marrow transplantation in adults. Journal of Clinical Oncology. 12: 2187-2192. PMID 7931488 DOI: 10.1200/Jco.1994.12.10.2187  0.344
1994 Zhu WM, Dong WF, Minden M. Alternate splicing creates two forms of the human kit protein. Leukemia & Lymphoma. 12: 441-7. PMID 7514064 DOI: 10.3109/10428199409073786  0.72
1994 Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature. 367: 645-648. PMID 7509044 DOI: 10.1038/367645A0  0.413
1991 Martinez-Valdez H, Takihara Y, Champagne E, Minden M, Mak TW, Cohen A. Differential regulation of γ and δ T cell antigen receptor gene expression by phorbol esters and Ca2+ ionophores in the acute lymphocyte leukemia DND41 cell line European Journal of Immunology. 21: 2625-2628. PMID 1833206 DOI: 10.1002/Eji.1830211048  0.344
1990 Lu M, Dubé I, Raimondi S, Carroll A, Zhao Y, Minden M, Sutherland P. Molecular characterization of the t(10;14) translocation breakpoints in T-cell acute lymphoblastic leukemia: further evidence for illegitimate physiological recombination. Genes, Chromosomes & Cancer. 2: 217-22. PMID 2078512 DOI: 10.1002/Gcc.2870020309  0.377
1989 Hara J, Benedict S, Champagne E, Mak T, Minden M, Gelfand E. Relationship between rearrangement and transcription of the T-cell receptor alpha, beta, and gamma genes in B-precursor acute lymphoblastic leukemia Blood. 73: 500-508. DOI: 10.1182/Blood.V73.2.500.Bloodjournal732500  0.335
1988 Takihara Y, Tkachuk D, Michalopoulos E, Champagne E, Reimann J, Minden M, Mak TW. Sequence and organization of the diversity, joining, and constant region genes of the human T-cell δ-chain locus Proceedings of the National Academy of Sciences of the United States of America. 85: 6097-6101. PMID 3413078 DOI: 10.1073/Pnas.85.16.6097  0.304
1988 Hara J, Benedict SH, Champagne E, Mak TW, Minden M, Gelfand EW. Comparison of T cell receptor alpha, beta, and gamma gene rearrangement and expression in T cell acute lymphoblastic leukemia. The Journal of Clinical Investigation. 81: 989-96. PMID 3162460 DOI: 10.1172/Jci113453  0.353
1988 Hara J, Benedict SH, Champagne E, Takihara Y, Mak TW, Minden M, Gelfand EW. T cell receptor delta gene rearrangements in acute lymphoblastic leukemia. The Journal of Clinical Investigation. 82: 1974-82. PMID 2848865 DOI: 10.1172/Jci113817  0.375
1987 Lewis WH, Billingsley GD, Cox DW, Gerhard DS, Dafoe LA, Mak TW, Minden M. An RFLP associated with the human T-cell antigen receptor alpha chain locus. Nucleic Acids Research. 15: 6760. PMID 2888086 DOI: 10.1093/Nar/15.16.6760  0.302
1986 Ha K, Minden M, Hozumi N, Gelfand EW. Single allelic Cμ gene rearrangements in patients with T cell and undifferentiated leukemia Leukemia Research. 10: 1-8. PMID 3080641 DOI: 10.1016/0145-2126(86)90098-6  0.426
1985 Tawa A, Hozumi N, Minden M, Mak TW, Gelfand EW. Rearrangement of the T-Cell Receptor β-Chain Gene in Non-T-Cell, Non-B-Cell Acute Lymphoblastic Leukemia of Childhood The New England Journal of Medicine. 313: 1033-1037. PMID 3930961 DOI: 10.1056/Nejm198510243131701  0.39
1985 Lewis WH, Michalopoulos EE, Williams DL, Minden MD, Mak TW. Breakpoints in the human T-cell antigen receptor alpha-chain locus in two T-cell leukaemia patients with chromosomal translocations. Nature. 317: 544-6. PMID 3876514 DOI: 10.1038/317544a0  0.311
1985 Yanagi Y, Chan A, Chin B, Minden M, Mak TW. Analysis of cDNA clones specific for human T cells and the alpha and beta chains of the T-cell receptor heterodimer from a human T-cell line. Proceedings of the National Academy of Sciences of the United States of America. 82: 3430-4. PMID 3873654 DOI: 10.1073/Pnas.82.10.3430  0.343
1985 Minden MD, Toyonaga B, Ha K, Yanagi Y, Chin B, Gelfand E, Mak T. Somatic rearrangement of T-cell antigen receptor gene in human T-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America. 82: 1224-7. PMID 3856257 DOI: 10.1073/pnas.82.4.1224  0.338
1985 Ha K, Minden M, Hozumi N, Gelfand EW. Phenotypic heterogeneity at the DNA level in childhood leukemia with a mediastinal mass Cancer. 56: 509-513. PMID 2408736 DOI: 10.1002/1097-0142(19850801)56:3<509::Aid-Cncr2820560317>3.0.Co;2-2  0.38
1984 Ha K, Minden M, Hozumi N, Gelfand EW. Immunoglobulin mu-chain gene rearrangement in a patient with T cell acute lymphoblastic leukemia. Journal of Clinical Investigation. 73: 1232-1236. PMID 6423668 DOI: 10.1172/Jci111310  0.436
1981 Major PP, Griffin JD, Minden M, Kufe DW. A blast subclone of the HL-60 human promyelocytic cell line. Leukemia Research. 5: 429-30. PMID 6945469 DOI: 10.1016/0145-2126(81)90018-7  0.316
Show low-probability matches.